According to the database "Production of Medicinal Products in Russia" from the analytical company RNC Pharma, in the first two months of 2026, pharmaceutical companies localized in Russia released over 630.4 million packages of finished medicinal products (FMPs) into circulation, equivalent to 12.8 billion minimum dosage units (MDU). Compared to January–February 2025, the physical volume of drug production increased by 6.7% in packages, while in minimum dosage units it adjusted downward by 0.8%. In the first two months of the current year, the total production volume of finished medicinal products in our country reached RUB 164.9 billion (at manufacturer selling prices, including VAT). Compared to the same period last year, production growth was recorded at 13.8% in ruble terms.

In the first month of 2026, pharmaceutical companies localized in our country released approximately 306 million packages, or 6 billion MDU, into circulation. Compared to January 2025, production increased by nearly 10% in packages. In February, FMP production increased to 324.7 million packages, equivalent to 6.8 billion MDU. The monetary value of drug shipments in January 2026 reached RUB 76.1 billion, which is 9.9% higher than a year earlier, and in February 2026, FMPs worth RUB 88.9 billion were produced, representing a 17.4% increase compared to February 2025.

It is worth noting that the production of OTC drugs has been consistently declining over the past three years. In 2025, production of the over-the-counter segment decreased by 7.7% in packages compared to the previous year. Meanwhile, the Rx segment, conversely, showed growth of 3.7% in packages. As a result, the share of prescription drugs in the total volume of drugs produced last year exceeded 52% in packages. Interestingly, the overall dominance of prescription drugs in the national production volume over the past 14 months was characteristic of all calendar months except January 2025 and January 2026.

Within the TOP-30 Rx drug brands, leading in terms of physical production volume, most showed significant shipment growth in January–February 2026. The highest growth rate among them was demonstrated by unbranded Oseltamivir, which was produced by seven domestic companies during the reporting period — compared to January–February 2025, the total production volume of the drug increased 3-fold in packages. Production volumes also tripled for the drug Prevenar (Pfizer), which is manufactured at the Petrovax plant in Podolsk.

Among the TOP-30 OTC brands, the highest growth in the first two months of the current year was shown by the brand Miramistin (Infamed), with production volume increasing 43-fold over the year. From January to February 2026, the manufacturer released 2.9 million packages of the antiseptic. In 2025, the peak production figures for Miramistin were recorded in May–June, when about 4.5 million packages were shipped to the market over the two months. Also noteworthy here is Rimantadine, produced by 8 companies, with the main manufacturer at the beginning of the year being Usolye-Sibirsky Chemical Pharmaceutical Plant.

Fig. Production Volume of Finished Medicinal Products in Russia (including the output of foreign pharmaceutical companies at their own and contract sites) by Rx and OTC Categories in January 2025 – February 2026, in Physical Terms (packages)